Cited by 4Cell death mechanisms and regulationCancer-related Molecular PathwaysLung Cancer Research Studies

Defective expression of FasL and Bax in human lung cancer

Badillo-Almaraz, I., Badillo-Salas, C., Villalobos, R., Avalos-D�az, E., Herrera-Esparza, R.·2003·Clinical and Experimental Medicine

Abstract

The present studies investigated whether FasL and Bax genes are expressed in pleuro-pulmonary biopsies from patients with lung cancer. FasL, Bax, and TNFalpha mRNAs were detected in 19 biopsies of primary or metastasic lung cancer by fluorescent in situ hybridization assays. Fluorescent probes were produced by polymerase chain reaction using a human spleen lambda gt11 library and specific primers for FasL, Bax, and TNFalpha. Proteins were detected by immunohistochemistry using monoclonal anti- FasL, anti-Bax, and anti-TNFalpha antibodies. Chromatin fragmentation was detected by TUNEL. Seven negative samples from subjects without lung pathology were obtained during legal autopsies and 12 positive control biopsies from patients with lung infections were also included. Sixty-eight percent of lung cancer biopsies exhibited FasL; Bax was expressed in 68% and TNFalpha in 63%. FasL protein was detected in 21%, Bax protein in 26%, and TNFalpha was present in 31% of cancer biopsies. A low degree of apoptosis in lung cancer was demonstrated by TUNEL assays. A defect in FasL, Bax, and TNFalpha gene expression was found in lung cancer biopsies. Some tumors normally expressed the mRNA of FasL, Bax, or TNFalpha, but their proteins were absent, or were non-functional, since TUNEL assays were negative. Such a failure would contribute to cancer cell survival and dissemination.

Integrity signals

Registry

Crossref · 10.1007/s10238-003-0012-1

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Faslg protein is only detected in a small fraction of human lung tumors.

    “Faslg mRNA is expressed normally in human lung tumors; however, the Faslg protein is only detected in a small fraction (Badillo-Almaraz et al., 2003).”

    From Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21 (2010) · cites this paper as Badillo-Almaraz et al., 2003

  • Faslg mRNA is expressed normally in human lung tumors.

    “Faslg mRNA is expressed normally in human lung tumors; however, the Faslg protein is only detected in a small fraction (Badillo-Almaraz et al., 2003).”

    From Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21 (2010) · cites this paper as Badillo-Almaraz et al., 2003

The citation lists haven’t been fetched yet

Cited by 4

Authors
Badillo-Almaraz, I., Badillo-Salas, C., Villalobos, R., Avalos-D�az, E., & Herrera-Esparza, R.
Affiliations
Universidad Autónoma de Zacatecas "Francisco García Salinas" (MX)
Venue
Clinical and Experimental Medicine
Published
2003-09-01
Volume
3
Issue
2
Pages
106-112
ISSN
  • 1591-8890 (ISSN-L)
  • 1591-9528
OpenAlex
W2078208450
Cited by
4
References
0
Citations by year
2020: 1
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical and Experimental Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
lung cancer, Fas ligand, Bax, TNF-α, apoptosis, tumor cell survival, metastasis, protein expression, TUNEL
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Membrane Glycoproteins, Middle Aged, Proto-Oncogene Proteins, RNA, Messenger, Tumor Necrosis Factor-alpha, In Situ Hybridization, Fluorescence, Proto-Oncogene Proteins c-bcl-2, In Situ Nick-End Labeling, bcl-2-Associated X Protein, Fas Ligand Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review